Amgen Stock Forecast, Price & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMGN stock has increased by 14.4% and is now trading at $227.16.
View which stocks have been most impacted by COVID-19.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 13 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Amgen.

Amgen will be holding an earnings conference call on Wednesday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Tuesday, July, 28th. The medical research company reported $4.25 EPS for the quarter, beating analysts' consensus estimates of $3.81 by $0.44. The medical research company earned $6.21 billion during the quarter, compared to analysts' expectations of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. Amgen's revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $3.97 EPS.
View Amgen's earnings history.

Amgen declared a quarterly dividend on Wednesday, October 21st. Investors of record on Monday, November 16th will be paid a dividend of $1.60 per share on Tuesday, December 8th. This represents a $6.40 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date is Friday, November 13th.
View Amgen's dividend history.

Amgen updated its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $15.10-15.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.63. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.38 billion.

28 brokers have issued 12 month target prices for Amgen's stock. Their forecasts range from $185.00 to $300.00. On average, they anticipate Amgen's stock price to reach $255.48 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price.
View analysts' price targets for Amgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional investors include LSV Asset Management (0.47%), Candriam Luxembourg S.C.A. (0.22%), Envestnet Asset Management Inc. (0.09%), Bartlett & Co. LLC (0.07%), Nisa Investment Advisors LLC (0.05%) and Retirement Systems of Alabama (0.04%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Cardinal Capital Management Inc., Wedge Capital Management L L P NC, Standard Life Aberdeen plc, DNB Asset Management AS, Redpoint Investment Management Pty Ltd, Pacer Advisors Inc., and Retirement Systems of Alabama. Company insiders that have sold Amgen company stock in the last year include David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Boston Trust Walden Corp, State of Alaska Department of Revenue, Contravisory Investment Management Inc., USA Financial Portformulas Corp, CHURCHILL MANAGEMENT Corp, Avantax Advisory Services Inc., and Hall Laurie J Trustee.
View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $227.16.

Amgen has a market capitalization of $133.05 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]